E. Alava, D. Tos, and A. , Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.21, pp.204-213, 2010.

G. Rosen, M. Murphy, A. Huvos, M. Gutierrez, and R. Marcove, Chemotherapy,en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma, Cancer, vol.32, issue.1, pp.1-11, 1976.
DOI : 10.1002/1097-0142(197601)37:1<1::AID-CNCR2820370102>3.0.CO;2-3

K. Mori, K. Ando, and D. Heymann, Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases, Expert Review of Anticancer Therapy, vol.8, issue.2, pp.151-154, 2008.
DOI : 10.1586/14737140.8.2.151

K. Ando, K. Mori, N. Corradini, F. Redini, and D. Heymann, Mifamurtide for the treatment of nonmetastatic osteosarcoma, Expert Opinion on Pharmacotherapy, vol.50, issue.1, pp.285-292, 2011.
DOI : 10.1007/BF01741788

URL : https://hal.archives-ouvertes.fr/inserm-00667530

M. Graaf, D. Richel, C. Van-noorden, and H. Guchelaar, Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer, Cancer Treatment Reviews, vol.30, issue.7, pp.609-641, 2004.
DOI : 10.1016/j.ctrv.2004.06.010

W. Maltese, R. Defendini, R. Green, K. Sheridan, and D. Donley, Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase., Journal of Clinical Investigation, vol.76, issue.5, pp.761748-1754, 1985.
DOI : 10.1172/JCI112165